Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)

Award Number: R44CA278187
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/07/2023
PERIOD OF PERFORMANCE END DATE: 06/30/2027

Group Awards By:

View Award Description

A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC) - Prostate cancer (PC) is the second leading cause of cancer-related death among American men, and the vast majority of these deaths are due to metastatic, castration-resistant PC (mCRPC). Androgen suppression therapy (AST) is used to treat PC patients, which comprise of: (1) androgen deprivation therapy (ADT) with LHRH agonists or antagonists; (2) blocking CYP17-mediated androgen synthesis with abiraterone; and (3) androgen receptor (AR) antagonists such as enzalutamide and others. While AR can significantly prolong overall survival (OS) of patients with various stages of PC, acquired resistance to either is inevitable, after which limited treatment options exist. Only about 35% of men respond to enzalutamide after developing resistance to abiraterone [1]. There is therefore a significant unmet need for new mCRPC treatments that act orthogonally and synergistically with existing AST to increase and prolong its efficacy in mCRPC. The chemokine receptor isoforms CXCR1 and CXCR2 (CXCR1/2) are validated as orthogonal therapeutic targets in mCRPC. Tumor-secreted CXCR1/2 ligands such as CXCL6 and CXCL8 (IL-8) mediate resistance to ASTs, exerting protumorigenic effects by binding surface CXCR1/2 on TAMs [2], MDSCs [3-8] and AR negative (AR-) neuroendocrine (NE) cancer cells [9] in the PC TME. MDSCs are significantly elevated in patient biopsies with CRPC vs. pre-ADT [3], as is expression of CXCL6 [7] and CXCL8 [5, 10]. Higher patient baseline serum CXCL8 pre-ADT was prognostic for shorter OS and time to CRPC independent of docetaxel, disease burden, and time of metastases [11]. Circulating MDSCs positively correlated with clinical stage, and inversely with OS (median OS of 19 vs. 55 months with high vs. low MDSCs) [12, 13]. We hypothesize that combining CXCR1/2 blockade with standard of care (enzalutamide) in mCRPC patients progressing on first-line abiraterone will afford enhanced efficacy vs. historical standard of care efficacy in the same population. SX-682 is a clinical-stage, small-molecule CXCR1/2 inhibitor validated in numerous published pre-clinical cancer models including mCRPC, and which exhibits activity in patients with melanoma, pancreatic adenocarcinoma and myelodysplastic syndromes. Through execution of the Specific Aims, we will advance SX-682 through critical proof-of-concept (POC) efficacy testing in the first ever phase 2 one-arm, open-label trial in mCRPC of a CXCR1/2 inhibitor with enzalutamide in patients failing abiraterone. The trial will enroll 53 evaluable patients with mCRPC diagnosis with (a) any histology, (b) measurable disease at enrollment, and (c) currently on or previously on abiraterone with prednisone and with rising PSA (a rising PSA requires at least 3 measurements obtained at least 1 week apart showing increase from nadir with the last level above 2 ng/mL). The primary endpoint is clinical benefit (CB), wherein CB is a composite endpoint defined as 1) RECIST 1.1 CR or PR, 2) confirmed PSA50 decline, or 3) prolonged stable disease by RECIST/PCWG3 criteria for ≥ 6 months. If successful, SX-682 would be a highly valuable new addition to the existing mCRPC treatment landscape.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $575,793 )
2026	2026	SYNTRIX BIOSYSTEMS INC.	215 CLAY ST NW	AUBURN	WA	98001	KING	USA	Cancer Treatment Research	000	4	7/31/2026	NON-COMPETING CONTINUATION	$575,793
														Subtotal = $575,793

Issue Date FY: 2025 ( Subtotal = $903,852 )
2025	2025	SYNTRIX BIOSYSTEMS INC.	215 CLAY ST NW	AUBURN	WA	98001	KING	USA	Cancer Treatment Research	000	3	6/6/2025	NON-COMPETING CONTINUATION	$679,155
2025	2025	SYNTRIX BIOSYSTEMS INC.	215 CLAY ST NW	AUBURN	WA	98001	KING	USA	Cancer Treatment Research	001	3	8/14/2025	NON-COMPETING CONTINUATION	$224,697
														Subtotal = $903,852

Issue Date FY: 2024 ( Subtotal = $745,050 )
2024	2024	SYNTRIX BIOSYSTEMS INC.	215 CLAY ST NW	AUBURN	WA	98001	KING	USA	Cancer Treatment Research	000	2	6/12/2024	NON-COMPETING CONTINUATION	$745,050
														Subtotal = $745,050

Issue Date FY: 2023 ( Subtotal = $400,000 )
2023	2023	SYNTRIX BIOSYSTEMS INC.	215 CLAY ST NW	AUBURN	WA	98001	KING	USA	Cancer Treatment Research	001	1	8/21/2023	NEW	$0
2023	2023	SYNTRIX BIOSYSTEMS, INC.	215 CLAY ST NW STE B-5	AUBURN	WA	98001	KING	USA	Cancer Treatment Research	000	1	7/7/2023	NEW	$400,000
														Subtotal = $400,000

Grand Total All Awards = $2,624,695

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)

Award Number: R44CA278187

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/07/2023

PERIOD OF PERFORMANCE END DATE: 06/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer